Remedent : Annual Report for Year Ended March 31, 2022

REMEDENT INC.

State of Incorporation: Nevada

Company Address: Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium

________________________________

Telephone Number: 011 32 9 241 58 80

Corporate Website: https://remedent.com

Company Email:[e-mail]

________________________________

SIC Code: 3843 - Dental Equipment and Supplies

Annual Report

For the period ending: March 31, 2022

(the "Reporting Period")

As of June 27, 2022, the number of shares outstanding of our Common Stock was: 19,995,969.

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 19,995,969.

As of March 31, 2022, the number of shares outstanding of our Common Stock was: 19,995,969.

As of March 31, 2021, the number of shares outstanding of our Common Stock was: 19,995,969.

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes:  No: 

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No: 

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes:  No: 

Annual Report - Remedent, Inc.

Page 1 of 70

Item 1 Name and address(es) of the issuer and its predecessors (if any).

1. Current Name of the Company and Any Names Used by Predecessor Entities

We were originally incorporated under the laws of Arizona in September 1996 under the name Remedent USA, Inc. In October 1998, we were acquired by Resort World Enterprises, Inc., a Nevada corporation (incorporated July 31, 1986) in a share exchange, and we immediately changed our name to Remedent USA, Inc. and later to Remedent, Inc. on June 2, 2005. The fiscal year end of the Company is March 31st.

In this document Remedent, Inc. and its subsidiaries are referred to as "Remedent", the "issuer", the "Company," "we," "our" or "us".

1. Jurisdiction(s) and Date of Incorporation or Organization.

Remedent, Inc. was incorporated on July 31, 1986, in the State of Nevada. The Company is active and in good standing with the State of Nevada as of the date of this report.

1. Trading Suspensions

The Company and its predecessors since inception have had no trading suspension orders issued by the United States Securities and Exchange Commission ("SEC").

1. Stock Split, Stock Dividend, Recapitalization, Merger, Acquisition, Spin-Off, or Reorganization

During the last three years, the Company has not undertaken a stock split, stock dividend, recapitalization, merger, acquisition, spin off, or reorganization.

1. The address of the issuer's principal executive offices.

Our principal executive office is: Zuiderlaan 1-3, bus 8, 9000 Gent, Belgium

Our telephone number is: 011 32 9 241 58 80

Our email address is: [e-mail]

Our website address is: Corporate Website: https://remedent.com

1. The Address(es) of the Issuer's Principal Place of Business.

Check box if principal executive office and principal place of business are the same address: 

1. Bankruptcy, Receivership, or Any Similar Proceeding.

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: 

Item 2 Security Information

1. Security Information.

Annual Report - Remedent, Inc.

Page 2 of 70

Trading symbol:	OTC REMI.PK
Exact title and class of securities outstanding:	Common Stock
CUSIP:	75954T 10 4
Par or stated value:	0.001
Total shares authorized:	60,000,000	as of date: June 27, 2022
Total shares outstanding:	19,995,969	as of date: June 27, 2022
Number of shares in the Public Float1:	12,733,496	as of date: June 27, 2022
Total number of shareholders of record:	202	as of date: June 27, 2022

1. All Additional Class(es) of Publicly Traded Securities (If Any):

None.

C. Transfer Agent

Name:	Issuer Direct Corporation
Phone:	919-481-4000.
Email:	[e-mail]
Address:	One Glenwood Ave, Suite 1001, Raleigh, NC 27603.
Is the Transfer Agent registered under the Exchange Act? Yes: 	No: ☐

1 "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Annual Report - Remedent, Inc.

Page 3 of 70

Item 3 Issuance History

1. Changes to the Number of Outstanding Shares.

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent period: 

Shares Outstanding as of Second Most Recent
Fiscal Year End:	*Right-click the rows below and select "Insert" to add rows as needed.
Opening Balance
Date 3/31/2021

Common: 19,995,969

Preferred: N/A

Date of

Transaction

Number of

Class of

Value of

Were the

Individual/

Reason for

Restricted

Exemption

Transaction

type (e.g.,

Shares

Securities

shares

shares

Entity Shares

share issuance

or

or

new

Issued (or

issued

issued at

were issued to

(e.g. for cash or

Unrestricted

Registration

issuance,

cancelled)

($/per

a discount

(entities must

debt conversion)

as of this

Type.

cancellation,

share) at

to market

have individual

-OR-

filing.

shares

Issuance

price at

with voting /

Nature of

returned to

the time

investment

Services

treasury)

of

control

Provided

issuance?

disclosed).

(Yes/No)

Shares Outstanding on Date of This Report:

Ending Balance

Date 06/29/2022

Common: 19,995,969

Preferred: N/A

1. Debt Securities, Including Promissory and Convertible Notes.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: 

Date of

Outstanding

Principal

Interest

Maturity

Conversion Terms (e.g.,

Name of Noteholder

Reason for

Note

Balance ($)

Amount

Accrued

Date

pricing mechanism for

(entities must have

Issuance (e.g.,

Issuance

at

($)

determining conversion of

individual with

Loan, Services,

Issuance

instrument to shares)

voting / investment

etc.)

($)

control disclosed).

Annual Report - Remedent, Inc.

Page 4 of 70

Item 4 Financial Statements.

1. U.S. GAAP or IFRS.

The following financial statements were prepared in accordance with:

1. • U.S. GAAP ☐ IFRS
2. Details About Party Who Prepared Financial Statements.

The financial statements for this reporting period were prepared by:

Name:	Philippe Van Acker
Title:	Chief Financial Officer and Chief Accounting Officer
Relationship to Issuer:	Director, Chief Financial Officer and Chief Accounting Officer

1. Financial Statements

1. Financial information for the issuer's most recent fiscal period.

The unaudited financial statements of the Company consisting of the consolidated balance sheet as of March 31, 2022 and March 31, 2021, and the related consolidated statements of operations, consolidated statements of comprehensive (loss), consolidated statement of stockholders' equity (deficit), consolidated statements of cash flows, and notes to consolidated financial statements for each of the years in the two

1. years period ended March 31, 2022 and March 31, 2021 are incorporated by reference, are attached as Appendix A to this Annual Report.

2. Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

The unaudited financial statements of the Company consisting of the consolidated balance sheets as of March 31, 2021 and March 31, 2020, and the related consolidated statements of operations, consolidated statements of comprehensive (loss), consolidated statement of stockholders' equity (deficit), consolidated statements of cash flows, and notes to consolidated financial statements for each of the years in the two

1. years period ended March 31, 2021 and March 31, 2020 are incorporated by reference and filed with the OTC Markets on September 24, 2021, as part of the Company's 2021 Annual Report.

Item 5 Issuer's Business, Products and Services.

1. Summarize the Issuer's Business Operations (If the issuer does not have current operations, state
   "no operations")

We specialize in the research, development, and manufacturing of oral care and cosmetic dentistry products. We are one of the leading manufacturers of cosmetic dentistry products in Europe. Leveraging our knowledge of regulatory requirements regarding dental products and management's experience in the needs of the professional dental community, we design, develop, manufacture and distribute our cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, Middle East and the United States.

Annual Report - Remedent, Inc.

Page 5 of 70